Search

This year’s Emerging Leader in Molecular Spectroscopy Award recipient is Joseph P. Smith of Merck, whose research is significantly influencing pharmaceutical process development through his work in various spectroscopic techniques, biocatalysis, protein engineering, vaccine production, and advanced data analysis methods. [ABSTRACT FROM AUTHOR]

The author recounts various aspects of his long career as CEO/Chief Executive Officer of the medical device company Medtronic, and describes his True North concept. He also describes the leadership transition in today's organizations to new generations. He believes that the old style of leadership is "rapidly being replaced by leaders with high levels of emotional intelligence who are committed to empowering people to reach their full potential." For additional context, he provides quotes from Ralph Lauren CEO Patrice Louvet, OneTrust founder Kabir Barday, former Kroger CEO Dave Dillon, and Levi Strauss CEO Chip Bergh. The author describes former Merck CEO Ken Frazier as an exemplar of "taking great personal risks that require moral courage." A chart compares characteristics of 20th and 21st century leaders. For instance, in Philosophy, the 20th century way was command‐and‐control, whereas now it is authentic leadership. Within Motivation; before it was self‐interest; now it is the institutions' best interest. For personal measurement, 20th century was external validation; 21st century is intrinsic contribution. The author concludes: "In today's complex world, we need emerging leaders to step up to the challenges to lead with their hearts, not just their heads, to make this world better for everyone." [ABSTRACT FROM AUTHOR]

The article focuses on Merck KGaA's agreement to sell its surface solutions business unit to Global New Material International Holdings Ltd. for 665 million euro in cash, with plans to use the proceeds to bolster its core businesses.

Merck KGaA has announced its plans to acquire a US-based life science firm for $600 million. The acquisition is expected to close in the third quarter of 2024, pending regulatory clearance and other closing conditions. This move is part of Merck's strategy to expand its bioprocessing expertise and portfolio in order to provide solutions for viral vector development and manufacturing. The specific details of the life science firm and the transaction have not been disclosed. [Extracted from the article]

Eli Lilly and Co. has announced an additional investment of $5.3 billion in the expansion of its active pharmaceutical ingredients (API) manufacturing site in Lebanon, Indiana. This investment doubles the company's planned investment and represents the largest manufacturing investment in synthetic medicine API in US history. The expansion will enhance Lilly's capacity to develop new manufacturing sites in the US and Europe. Additionally, Merck KGaA has agreed to acquire a US-based life science firm for $600 million, and Bionova Scientific plans to invest $100 million in expanding into plasmid DNA production in Texas. Wacker Chemie AG has acquired Bio Med Sciences Inc. to expand its business in silicone-coated healthcare products. [Extracted from the article]

George describes former Merck CEO Ken Frazier as an exemplar of "taking great personal risks that require moral courage." George concludes: "In today's complex world, we need emerging leaders to step up to the challenges to lead with their hearts, not just their heads, to make this world better for everyone." How can leaders of today and tomorrow meet the significant, seemingly unprecedented challenges they face?. [Extracted from the article]

The article evaluates glaucoma medication Zioptan offered by Merck, Eye4 smart glasses offered by Eyedaptic, and Meivertor, eyelid eversion tool, offered by Meivertor.

The article reports on pharmaceutical firm Merck KGaA's acquisition of chemical company Sigma-Aldrich Corp. for $17 billion. It mentions the concern of European Union regulators on the deal which could give Merck significant market share in the laboratory chemical market. It also notes that the merger will lead to a new business unit known as MilliporeSigma in the U.S.

The article offers brief information on several commercial products including the water purification system AFS 40E from Merck KGaA, a combustion ion Chromatograph from Metrohm USA Inc. and liquid chromatography system 1290 Infinity 2D-LC from Agilent Technologies Inc.

The article presents news briefs as of February 1, 2019. Topics discussed include the IChemE Safety Centre has made IChemE's historic Accident Database available online for anyone to access, free of charge; Shell has opened wells and begun feeding gas to its Prelude floating liquefied natural gas (FLNG) facility; and 30th anniversary of Merck which received a prize for chemical engineering students at Cork Institute of Technology (CIT).

The article presents a summary of merger and acquisition transactions in Europe announced between October 1, 2009 and March 31, 2010. Among those cited include Royal Bank of Scotland Group PLC and Freshfields Bruckhaus Deringer in Great Britain, Millipore Corp. and Merck KGaA in Germany and Areva T&D SA and Alstom SA and Schneider Electric SA in France.

Focuses on the global expansion plans of Merck KGaA. Concentration on chemicals and laboratory products and pharmaceuticals; Plan for initial public offering of distribution business operated under VWR International; Development of drug for treatment of colorectal cancer.

Presents news briefs on chemical industry in Europe as of September 1999. Acquisition of Johnson Matthey's electronic materials unit by AlliedSignal; Operating profit of Merck KGaA in the first-half of 1999; Decline of the first-half pretax profits of Sud-Chemie (Munich).

The article discusses plans of the Merck KGaA to leave the over-the-counter (OTC) drug business. It mentions Merck's OTC business markets products such as Bion vitamins and Seven Seas cod liver oil. It also mentions Johnson & Johnson has long run an OTC business with brands such as Tylenol and Benadryl. It also mentions Sanofi acquired the Chattem in 2010.

The article offers information on the series A funding received by Indi Molecular worth $11.5 million which will be used to support the company's development of small peptides which acts as antibodies. It mentions that the funding was led by Merck KgaA, Sabey, and Legend Capital's venture arm along with investors from the company.

The article reports on partnership of Merck KGaA and Swiss ultraviolet (UV) coatings firm Schmid Rhyner to commercialize Merck's three-dimensional-effect technology in the package printing market.

The article offers information on the decision of chemical company Merck KGaA based in Darmstadt, Germany to continue its chemical and pharmaceutical businesses despite separation of several companies such as Solvay and Hoechst. It mentions insight from Stefan Oschmann, chief executive officer (CEO) of Merck, regarding the financial performance of the company along with its expansion in the health care sector.

The article discusses acquisition of chemical company Sigma-Aldrich by its fellow company Merck KGaA and relevance of Honeywell Research Chemicals for the acquisition. Topics discussed include decision of European Commission (EC) regarding selling of Sigma-Aldrich's European inorganics and solvents business before the acquisition, Honeywell's announcement regarding acquisition of the business and views of Arnaugh Verhaeghe, general manager of Honeywell, regarding the same.

The article focuses on the move of Merck KGaA and Versum Materials to sign a definitive agreement for Merck to acquire Versum for $53 per share.

The article informs that Versum Materials is planning to accept a revised takeover proposal from Merck KGaA and terminate its previously announced merger with Entegris, and also mentions that the combination will create portfolios such as electronic materials, and equipment for the semiconductor.

This article announces that Merck KGaA has proposed a $5.9 billion bid to acquire the chemicals company Versum Materials.

The article focuses on profile of the company MilliporeSigma which has been leader in life science industry along with support of the gas chromatography techniques and mentions headquarter of the company Darmstadt, Germany.

The article focuses on the court battle by pharmaceutical companies Merck KGaA in Germany and Merck & Co. Inc. in the U.S. regarding the use of Merck name. Topics mentioned include the lawsuit filed by Merck & Co. against Merck KGaA due to improper use of Merck name and cybersquatting, the agreement by two firms in 1955, and the establishment of U.S. Merck as a subsidiary of Merck KGa.

The article presents an interview with Joseph Plurad of the chemical supplier EMD Millipore. Topics discussed include contaminants such as organics, ions and particles that could be present in ultrapure water, practices for using a water system to generate chromatography-grade water and reduction in exposure to contamination by picking the right size and material of construction.

The article informs that company Procter & Gamble has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.

The article focuses on the pharmaceutical company Merck KGaA selling off its consumer health business with brands like Seven Seas vitamins and Oral-B toothpaste to chemical company Procter & Gamble.

The article reports that Pfizer is considering the sale of its consumer health care division, which is one of the world's biggest makers of over-the-counter drugs.

The article reports that German-firm Merck is evaluating strategic options for its consumer health business, including a potential full or partial sale, or partnerships to its biosimilar business.

The article reports that pharmaceutical company Merck KGaA has been accused by European antitrust regulators for holding back important information before completing its acquisition of lab chemicals maker Sigma-Aldrich for 17 billion dollars.

The article reports on agreement of Merck KGaA with privately held firm F-star, that gives Merck an exclusive option to acquire five bispecific antibodies against immuno-oncology targets.

The article informs that liquid-crystal display materials maker Merck KGaA has partnered with Cambridge, England-based flexible electronics producer FlexEnable to develop a new generation of Liquid Crystal Displays (LCDs) with complex surfaces and shapes.

The article discusses the acquisition of Grzybowski Scientific Inventions (GSI) by MilliporeSigma, the life science division of Merck KGaA.

The article reports on the announcement by the chemicals company Merck KGaA regarding the divestment of its biosimilars business to Fresenius, a healthcare group based in Bad Homburg, Germany.

The article reports on a collaboration between pharmaceutical firm Merck KGaA and the Indian materials engineering firm Steer on a processing technology to enhance the use of special effects pigments.

The article discusses some life changing events of researcher James Schiller and its relevance for his career in pharmaceutical industry. Topics discussed include an electrical accident in 1988 while pursuing studies at University of Delaware in Newark, Delaware that led him to lose his left arm and right leg, his role as a mass spectrometry analyst at LabCorp in 1996 and his role as bio analytical preclinical group at pharmaceutical company Merck.

The article reports that chemical firm Merck KGaA has taken full control of Peer+, a Dutch developer of liquid-crystal windows, by acquiring the 30 percent of the firm, in a move to offer smart windows that utilizes less energy in buildings.

This section offers news briefs from the chemical industry. It relates the plans of Mexichem to acquire the AlphaGary plastic compounding business of Rockwood Holdings for 300 million U.S. dollars. Summit Lubricant, a producer of specialty greases for military applications, has been acquired by Quaker Chemical. The Crop BioScience subsidiary of Merck KGaA will be acquired by Novozymes.

The article offers the insight of Dr. Karl-Ludwig Kley, chairman of the executive board of Merck KGaA on the growth and development of the pharmaceutical and chemical company. Kley states that the restructuring of the company brings back a business model that holds four segments with more than 10% profit margins. He says that Merck has no plans for merger and acquisition (M&A) in Chinese enterprises, however, they aim to build their own research and development (R&D) base in China.

This section offers news briefs on the chemical industry as of March 2010. Merck KGaA will enter an agreement worth 5.3 euros to purchase Millipore. Chevron announced that the ethylene unit of the Ras Laffan Olefins Co. (RLOC) in Ras Laffan, Qatar will begin its operations in March. Linde reported that its net profits for the fourth quarter of 2009 has rose by 5% compared to the same period in 2008.

The article offers news briefs concerning global chemical industry, as of November 2016, closure of a plant of Orion Engineered Carbons; partnership between Merck KGaA and Japan's Idemitsu Kosan; and profits raised by BioConsortia, a developer of yield-enhancing microbial crop treatments.

The article informs that global chemical company Merck KGaA is planning to spend 90 million U.S. dollars on a facility in Nantong, China, that supplies pharmaceutical services and products such as high-purity inorganic salts and cell culture media, as of November 2016.

The article reports that German pharmaceutical company Merck KGaA has increased the capacity of its biotech drug production in Spain in 2016 through the expansion of its facility inTres Cantos, Madrid.

The article offers news briefs related to business in the U.S. as of 2016 including the planned construction of a solution-butadiene rubber pilot plant of Trinseo, the license granted by Merck KGaA to coatings maker DurXtreme and the plan of Solvay to increase its sulfone polymers capacity.

The article reports on plans of German pharmaceutical firm Merck KGaA to built a plant that will produce LC window (LCW) modules that are used to darken glass to provide sun protection for business expansion.

The article reports that Merck KGaA has doubled the size of its corporate venture fund and expanded it beyond the biopharmaceutical sector.

The article reports on the financial performance of Darmstadt, Germany-based life sciences and performance materials company Merck KGaA as of first quarter of 2016, highlighting its increased sales on organic growth following merger and acquisition of chemicals company Sigma-Aldrich Co.

The article reports on the plan of German pharmaceutical company Merck KGaA to increase capacity for its viral and gene therapy products in Carlsbad, California under the Good Manufacturing Practice program of the U.S. Food and Drug Administration.